Sarepta Therapeutics, Inc.
SRPT
$18.10
-$0.32-1.74%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | -102.48% | 173.96% | -277.84% | -635.38% | 2,947.86% |
| Total Depreciation and Amortization | -3.98% | 6.17% | -49.76% | 88.15% | 24.33% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,084.23% | -69.08% | 45.77% | 71.83% | -90.98% |
| Change in Net Operating Assets | 189.38% | -108.05% | 371.62% | 86.51% | 209.16% |
| Cash from Operations | -24.59% | 65.26% | 42.54% | 79.37% | 1,649.01% |
| Capital Expenditure | 98.25% | 95.23% | 90.57% | 38.45% | -9.01% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -245.01% | 46.55% | -87.56% | 378.86% | 192.28% |
| Cash from Investing | -389.88% | 53.85% | -87.41% | 280.40% | 132.69% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -57,465.79% | -7,688.16% | -51,566.18% | -- | -- |
| Issuance of Common Stock | -100.00% | -98.46% | -91.70% | 54.21% | -96.24% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -109.67% | -- | -- |
| Cash from Financing | 100.00% | -98.07% | -180.03% | -956.22% | -159.66% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -61.56% | 60.93% | -79.21% | 153.84% | 717.69% |